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Abstract 8 
Current information about the nutritional composition of milk fat is required for the consumer and therefore 9 
essential for the successful development of dairy industries as well as marketing their products. The progress 10 
in the knowledge concerning some milk fat components that possess biological properties and health benefits 11 
beyond their nutritional significance, have a growing interest in the dairy industry to design and formulate 12 
products that incorporate specific bioactive components derived from milk.  13 
In the last two decades, special attention has been paid to the fatty acid (FA) composition on all short, 14 
medium chain and branched fatty acid as well as linoleic conjugated acid (CLA) in milk and dairy products. 15 
Trans monounsaturated fatty acids profiles from dairy fat has gained increasing relevance because may have 16 
metabolic properties distinct from those of other origins, hydrogenation reaction for instance. Other minor 17 
lipid compounds with biological activity, phospholipids and cholesterol are part of the fat globule membrane. 18 
This review summarizes the current knowledge in milk fat research with a brief overview of the importance 19 
of dairy lipids as biological molecules with emphasis in the different bioactive compounds present in this 20 
fraction. 21 
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I. INTRODUCTION 31 
 32 
Lipids are one of the most important components of milk in terms of physical, organoleptic and nutritional 33 
properties they impart to dairy products.  However, as result of their content in saturated fatty acids and 34 
cholesterol, nutritionists have advised against consumption of milk fat. Nevertheless in the last decade it have 35 
been reported the presence in milk fat of lipid compounds that exert important biological activities as butyric 36 
acid, conjugated linolenic acid (CLA), sphingolipids as constituents of the milk fat globule membrane and 37 
liposoluble vitamins. These compounds have commercial application in the development of functional foods 38 
to promote human health and diseases prevention. In order to enhance their activity and therefore the positive 39 
effects of its consumption many studies are focused to obtain natural enrichment dairy products as well as 40 
isolation of these compounds to be used as functional ingredients. A deeper knowledge on the regulation of 41 
the metabolic pathways of these bioactive lipids and their potential positive effect in human heath will be 42 
essential in the formulation of these products with added value.  43 
In milk, lipids are present in the form of globules, with an average diameter of 3 µm in sheep milk to 5 µm 44 
in cow milk [1]. Fat globules contain a hydrophobic lipid core, consisting mainly of triglycerides (TAG), 45 
surrounded by a membrane mainly compose of phospholipids and glycoproteins. The structure and 46 
composition of the milk fat globule membrane (MFGM) is similar to all ruminant species and it represents 47 
approximately 1% of total milk fat volume [2]. Among the main health beneficial components of MFGM are 48 
cholesterolemia-lowering factor and anticarcinogenic agents [3] which allow considering MFGM as a 49 
potential nutraceutical. Furthermore milk lipids are carriers for important vitamins as A, D, E y K and 50 
carotenoids.  51 
 52 
II. TRIACYLGLYCERIDES (TAG) 53 
TAG constitutes the biggest group of milk fat lipids (nearly 98%), including a large number of esterified 54 
fatty acids. TAG in milk fat present a wide range of molecular weights when distributed according to the 55 
number of carbon atoms (taking into account the sum of the carbon atoms of the three acyl radicals) from 56 
C26 to C54 [4]. Sheep and goat’s milk have a higher percentage of medium-chain TAG (C26-C36) than 57 
cow’s milk and a lower proportion of long chain TAG (C46-C54) [5]. Compared with TAG containing 58 
mainly long chain fatty acids those comprising saturated fatty acids with 6-10 carbons have lower melting 59 
points, smaller molecule size, and less energy dense. These chemical and physical properties affect their 60 
absorption and metabolism.  61 
Given the great variance of fatty acids in milk fat, interest in the biological effects of the position occupied by 62 
individual fatty acids on the TAG molecule and the lipoprotein metabolism remains intense because may be 63 
relevant to their effects on CVD. The FA distribution in the TAG is species specific and nonrandom, with 64 
most of the C4:0 and C6:0 esterified to the sn-3 position and the C16:0 occupies the sn-2 position. As the 65 
pancreatic lipase in the gut selectively hydrolyzes TAG at the sn-1 and sn-3 positions, short free fatty acids 66 
and 2-monoglycerides are produced. This unique position of C16:0 ensures that calcium in milk is highly 67 
absorbable.  68 
 69 
III. MILK FATTY ACID COMPOSITION 70 
 3 
Milk fat is a complex mixture of about 400 different fatty acids from 4 to 26 carbon atoms although only 71 
30 of these compounds are in a concentration above 0.1% and the rest are present in trace amounts [6]. 72 
Saturated (SFA) or unsaturated (with one to four double bonds), are mostly of even number of carbon atoms 73 
but there is also odd-numbered moieties (2%) as well as branched chain fatty acids. Milk from different 74 
species have characteristics fatty acid compositions: The content in short chain fatty acids: butyric (C4:0), 75 
caproic (C6:0), caprilic (C8:0) and capric (C10:0) acids are 2-3 fold higher in sheep than in goat’s milk [7].  76 
The five major acids from the quantitative point of view (C18:1, C16:0, C10:0, C14:0, and C18:0) account 77 
for more than 70% of the total fatty acids. The content of SFA in milk fat (~ 65%) has been associated with 78 
increments in the cardiovascular disease markers in plasma as LDL-cholesterol. On the other hand, only one 79 
third of SFA in milk, C12:0, C14:0 y C16:0 seems to be unhealthy when associated to an excessive 80 
consumption [8]. Recent studies have revealed that is more important to maintain a good balance among 81 
different fatty acids than the possible healthy or harmful effects they could exert individually [9,10,11,12]. 82 
Other studies concluded that those compounds considered as hypercholesterolemic may even have positive 83 
effects in moderate intake [13] and a recent meta-analysis of prospective epidemiologic studies [14] showed 84 
that there is no significant evidence for concluding that dietary saturated fat is associated with an increased 85 
risk of CHD or CVD.  86 
Concerning to short chain fatty acids, beneficial effects of these compounds have been reviewed [15]. 87 
These authors reported the capacity of those fatty acids to reduce body weight and mainly body fat.  They are 88 
particularly digestible, as they are hydrolysed preferentially from the TAG and transferred directly from the 89 
intestine to the portal circulation without resynthesis of TAG. Furthermore, these fatty acids are a preferred 90 
source of energy ( -oxidation). Given in moderate amounts, in diets with not high fat supply, they may 91 
actually reduce fasting lipid levels more than oils rich in mono- or polyunsaturated fatty acids [16]. The 92 
butyric acid (C4:0) is present in milk fat in concentrations ranged 2-5% and it has been described as an 93 
anticarcinogenic agent. At low concentrations butyric acid can inhibit growth in a wide range of human 94 
cancer cell lines [17] although it have been shown in animal studies that dietary fibers, which liberate a 95 
constant and elevated supply of butyrate to the colon, are most effective for prevention of chemically induced 96 
colon tumors. Furthermore, synergism between butyrate and other dietary components and common drugs in 97 
reducing cancer cell growth have also been shown [18]. On the other hand, the short and medium chain fatty 98 
acids (C4:0, C6:0, C8:0 and C10:0) can exert antimicrobial and antiviral activities both in vitro and in animal 99 
studies [19]. 100 
Stearic acid (C18:0) with an average concentration in milk fat of 11%, is considered as neutral from the 101 
point of view of human health and can reduce plasma cholesterol as well as oleic acid (C18:1 cis 9, 15-23% 102 
in milk fat). It is also interesting the presence of polyunsaturated fatty acids (PUFAs) as linoleic (18:2 cis 9, 103 
cis 12) and linolenic acids (18:3 cis 9, cis 12, cis 15) in amounts of 1-3% respectively and recognized 104 
positive effect on cardiovascular health. Finally indicate that milk is the main source of conjugated linoleic 105 
acid (CLA) in the diet. It is known that the major CLA isomer (18:2 cis 9, trans 11) is a potent natural 106 
anticarcingenic agent [20]. 107 
Besides that, milk fat has other fatty acids as the branched chain fatty acids as 13-methyl tetradecanoic acid 108 
(iso-15:0), phytanic acid (3, 7, 11, 15-tetra methyl-16:0), and the derivative of the latter, pristanic acid, which 109 
are known to bind to nuclear receptors, with subsequent modification of gene expression. Others as phytanic 110 
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acid has been shown to decrease liver triglyceride accumulation in mouse models [21]. Palmitoleic acid 111 
(C16:1 cis 9), has been demonstrated to effect a hormone-like (lipokine) activation of glucose uptake in 112 
muscle cells [22]. Among milk fats, these FA are found in higher concentrations in goat’s milk and are 113 
relevant as contributors to the milk fat melting point and also useful in clinic studies as human intake markers 114 
of milk fat while they are no present in other animal fats [23].  115 
According to this, in the last years, studies have been accomplished resulting in high number of scientific 116 
publications with the aim to reconsider the significant activity of fatty acids present in milk fat and their 117 
effects on human health [9, 24, 25, 26, 27, 11, 12]. 118 
 119 
III.1 CONJUGATED LINOLEIC ACID (CLA) 120 
The generic name CLA is a collective term embracing all positional and geometric isomers of linoleic acid, 121 
which contain a conjugated double bond system. Data from in vitro studies and animal models have been used 122 
to suggest that the isomer C18:2 cis 9, trans 11 (known as rumenic acid, RA) is responsible for CLA 123 
anticarcinogenic and antiatherogenic properties, as well as a multiplicity of potentially beneficial effects on 124 
human health [28, 9, 29, 30, 31, 32]. 125 
Among ruminants, sheep’s milk fat contains one the highest level of CLA, and the major content of C18:1 126 
trans 11 (vaccenic acid, VA), its physiological precursor [33]. In the first studies concerning the total CLA 127 
mean content was described the following order: sheep> cow > goat milk fat, 1.2; 0.7 and 0.6 % of total fatty 128 
acids, respectively [34]. RA is the most abundant isomer and accounts for around 75 % of the total CLA. 129 
From initial studies showing their anticarcinogenic affects as inhibited epithelial tumors in animals [35], a 130 
high number of research works have been performed in the determination of their biological and 131 
physiological properties [20]. The available information on the effects of CLA in cancer cell metabolism 132 
together with their antiproliferative and apoptotic activities [36] place CLA as an interesting compound in 133 
cancer therapy. Even more, recent studies reported that high CLA intake through high fat content dairy 134 
products may reduce the risk of colon-rectal cancer [37]. 135 
There are many possible metabolic pathways involved in the anticancer activity of CLA. It has been 136 
suggested that CLA competes with arachidonic acid (C20:4) in the cyclooxygenase reaction then reducing 137 
the concentration of prostaglandins and thromboxane of the 2-series [38]. CLA can suppress cyclooxygenase 138 
gene expression and reduce the release of pro-inflammatory cytokines such as TNF-alpha and interleukin in 139 
animals [38] as well as also seem to activate the PPARs transcription factors, reduce the initial step in the 140 
activation of NF-kappa B thereby reducing cytokines, adhesion molecules and other induced by stress [39]. 141 
As mentioned, besides RA, other CLA isomers have been associated with several metabolic processes related 142 
to health. Thus the C18:2 trans 10, cis 12, has achieved a great relevance since it have been reported to 143 
promote weight loss [40,9] although it could cause decrease in glucose levels and plasma insulin resistance 144 
[41,42]. RA was tested in breast cancer cell cultures and concluded to act as a human estrogen blocking agent 145 
while C18:2 trans 9, trans 11 inhibits growing of colon cancer cells [43]. 146 
Studies in humans are scarce but in the last years some clinical trials have been carried out using CLA 147 
isomers mixtures. Thus, Tricon et al., [44] had showed that incorporation of RA and C18:2 trans 10, cis 12 148 
into the diet of healthy volunteers affects positively to plasma lipid levels leading to a significant reduction of 149 
the total cholesterol and triacylglycerides (TAG) concentrations mainly associated to RA while C18:2 trans 150 
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10, cis 12 appears not to be as beneficial to the CVD risk markers. Recent studies in obese and overweight 151 
children (6-10 yr old) consuming a CLA enriched chocolate milk, found attenuation in the BMI increment 152 
but did not improve plasma lipids or glucose and decreased HDL cholesterol level [45].  153 
About the other CLA isomers, the C18:2 cis 9 cis 11 has been shown to be also a blocking agent of 154 
estrogen signaling in human breast cancer cells in vitro assays [46]. Other studies have reported the potent 155 
inhibitory effect of C18:2 trans 9 trans 11 on the growth of human colon cancer cells [47] as well as 156 
antiproliferative and pro-apoptotic effects on bovine endothelial cells [48]. However, further research is 157 
needed in this field. 158 
 159 
III.2 TRANS FATTY ACIDS (TFA) 160 
 161 
TFA content in milk fat ranged from 2.5 to 5% of total fatty acids, depending on diet and season. Monoene 162 
TFAs are the main compounds in all species. In ruminant, sheep’s milk presented the highest quantities, after 163 
cows and lately goats milk fat. The pattern of C18:1 trans isomer distribution is however qualitatively 164 
identical in the three species [49]. TFA in dairy fat are not seen as bioactive lipids in a positive sense. But 165 
since TFA have come under scrutiny due to their influence on lipid levels and on other risk factors for CVD, 166 
the question whether all TFA are alike or whether TFA isomers from dairy fat may have metabolic properties 167 
distinct from those of other origins, hydrogenation reaction for instance, has gained increasing relevance 168 
[50]. 169 
The main source of TFA consumed daily by humans is partially hydrogenated vegetable fats and oils, 170 
although these compounds also occur naturally in ruminant milk result of partial biohydrogenation of PUFA 171 
caused by rumen microorganisms. There is a considerable overlap of TFA isomers in fats of ruminant origin 172 
and partially hydrogenated vegetable oils, with many isomers in common. However the isomer profile of 173 
hydrogenated vegetable fats is very different. During the hydrogenation of vegetable fats a wide range of 174 
trans monounsaturated fatty acids are principally formed (e.g. C18:1 trans 9, elaidic acid) while the main 175 
TFA in milk fat is C18:1 trans 11, VA [24]. The importance of VA lies in its already cited role as a precursor 176 
of the main isomer of CLA, rumenic acid (RA) physiologically the most relevant bioactive compound present 177 
in milk fat. This synthesis not only occurs in the bovine mammary gland [51, 52] but also in human and other 178 
animal tissues [53, 54, 55]. The rate of VA to total monoene TFA in milk fat is around 40-60% [56,49,57], 179 
whereas elaidic acid is only present in considerably smaller amounts (average of 5% of the total TFA). In 180 
contrast, the majority of hydrogenated vegetable oils have a TFA profile with a gauss distribution showing 181 
high concentrations of C18:1 trans 9 and trans 10.  182 
Individual TFA isomers could have differing physiological effects [58]. There is evidence of unfavorable 183 
effects of TFA from hydrogenated vegetable oils on LDL and other risk factors of atherosclerosis whereas, the 184 
predominant TFA in milk, VA, would not exert these detrimental effects [24,18]. Most of the studies reported 185 
that the positive association with the risk of CVD could be explained entirely by the intake of TFA from 186 
hydrogenated vegetable oils. Pfeuffer and Scherezenmeir [59] also compiled works addressing the effect of TFA 187 
intake on CVD. Several of the large prospective studies, which established the notion the intake of TFA increases 188 
CVD risk, showed a significant inverse association with intake of animal or dairy TFA, a non-significant inverse 189 
trend or at least no change with increasing intake of TFA from such sources [59].  Recent studies suggest that 190 
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TFA from animal sources did not lead to higher cardiovascular risk [60,61]. Also Tricon et al., [62] and 191 
Wanders et al., [63] found that increments in the concentrations of TVA and RA are not related to CVD  192 
 193 
IV. MINOR LIPID COMPOUNDS 194 
 195 
Milk presents complex lipids as phospholipids and different liposoluble compounds (sterols, -carotene 196 
and vitamins) with biological activity.  197 
Phospholipids are associated with the milk fat globule membrane (MFGM) and account for 0.5-1% of total 198 
milk lipids [64, 65]. Sphingolipids and their active metabolites, ceramides and sphingosines, were determined 199 
as effective bactericidal agents on pathogens and they are reported to have tumor-suppressing properties by 200 
influencing cell proliferation and are highly bioactive compounds with bacteriostatic and cholesterol-201 
lowering properties [9,18,66]. Further, some phospholipids exhibit antioxidative properties in dairy fat 202 
products with low water content [67]. However, to date, only very limited data are available on the 203 
phospholipids content in dairy products and the influence of processing and environmental variables on its 204 
concentration and relative distribution. The phospholipids proportions in the different ruminant milks are 205 
similar: Phosphatidylcholine (35%) phosphatidyl-ethanolamine (30%), and sphingomyelin (25%) are the 206 
major, with smaller amounts of phosphatidylinositol (5%) and phosphatidylserine (3%), [7]. 207 
Other molecules as ether lipids (alkyldiacylglycerols and alkylacylphospholipids) are present in milk lipid 208 
fraction at low amounts but have been also claimed as bioactive components [67]. These compounds are 209 
incorporated and accumulated in cell membranes and thereby influence biochemical and biophysical 210 
processes [18].  211 
The sterol fraction of milk fat and especially the cholesterol is of nutritional interest because high levels of 212 
cholesterol in plasma are associated with an increasing risk of CVD. Nevertheless today is well known 213 
trough analysis of the available epidemiological and clinical data that for the general population, dietary 214 
cholesterol makes no significant contribution to atherosclerosis and risk of CVD [68]. 215 
Cholesterol (about 260-270 mg /100 g fat) is also important for the resorption of fats and its role as 216 
precursor in the synthesis of steroid hormones. Small amounts of other sterols implicated in cholesterol 217 
biosynthesis have also been found in milk fat: lanosterol, dihydrolanosterol, desmosterol, and lathosterol.  218 
 219 
V. FINAL REMARKS  220 
 221 
The public perception of whole milk fat dairy products is a significant challenge that faces the dairy industry 222 
because of their perceived negative effects on human health. Besides, the current nutritional recommendations 223 
for these dairy products are that their consumption should be limited. However, milk is a complex food with a 224 
host of nutrients, and the conclusions from long-term studies and meta-analyses suggest a reduction in risk in 225 
the subjects with the highest dairy consumption relative to those with the lowest intake for almost all-cause 226 
deaths and diseases.  227 
The diversity of milk fat lipids, the variety of bioactive substances that it contains and their physiological 228 
functions remains poorly understood. Therefore, further research is required to establish the contribution of these 229 
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